AbramsDIJayCIShadeCS, et al. (2007) Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology68: 515–521.
2.
CollinsRBowmanLLandrayM, et al. (2020) The magic of randomization versus the myth of real-world evidence. N Engl J Med382: 674–678.
3.
DavisCLexchinJJeffersonT, et al. (2016) “Adaptive pathways” to drug authorisation: Adapting to industry?BMJ354: i4437.
4.
EllisRJToperoffWVaidaF, et al. (2009) Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. Neuropsychopharmacology34: 672–680.
5.
FranceD (2016) How to Survive a Plague: The Inside Story of How Activists and Scientists Tamed AIDS. London: Picador.
HatswellAJBaioGBerlinJA, et al. (2016) Regulatory approval of pharmaceuticals without a randomised controlled study: Analysis of EMA and FDA approvals 1999–2014. BMJ Open6: e011666.
8.
MartinJHCranswickN (2018) Care and concern with cannabinoids used therapeutically. Br J Clin Pharmacol84: 2455–2457.
National Academies of Sciences Engineering and Medicine (NASEM) (2017) The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies.
11.
PiomelliDCooperZAbramsD, et al. (2017) A guide to the National Academy of Science report on cannabis: An exclusive discussion with panel members. Cannabis Cannabinoid Res2: 155–159.
12.
SchlagA-KBaldwinDBarnesM, et al. (2020) Medical cannabis in the UK: From principle to practice. J Psychopharmacol34: 931–937.
13.
StockingsECampbellGHallWD, et al. (2018) Cannabis and cannabinoids for the treatment analysis of controlled and observational studies. Pain159: 1932–1954.
14.
WhitingPFWolffRFDeshpandeS, et al. (2015) Cannabinoids for medical use: A systematic review and meta-analysis. JAMA313: 2456–2473.
